Reprint

Angiogenesis in Cancers

Edited by
March 2023
274 pages
  • ISBN978-3-0365-6916-1 (Hardback)
  • ISBN978-3-0365-6917-8 (PDF)

This is a Reprint of the Special Issue Angiogenesis in Cancers that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

Tumor progression is linked to a switch in the balance between positive and negative regulators, and mainly depends on the release by inflammatory or neoplastic cells of specific growth factors. Inflammatory infiltration contributes to tumor progression and metastatic process, and there are many reports of associations between tumor inflammatory infiltration, progression and prognosis. New therapeutic approaches have been developed with the aim to control tumor progression through the targeting of different components of the tumor microenvironment. This reprint will be useful for anyone who wants to learn about cancer: professors and students at universities, scientists at research institutes, biotechnology, and pharmaceutical labs, and lawyers trying to understand the patent literature.

Format
  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
Keywords
RBP4; metastasis; breast cancer; angiogenesis; endothelial dysfunction; STAT3; VEGF; endothelin-1; resveratrol; gemcitabine; endoglin; ERKs; microvessel growth; lung cancer; angiogenesis; cancer; VEGF; anticancer; DLBCL; tumor microenvironment; angiogenesis; cell adhesion mediated drug resistance; tumor progression; angiogenesis; VEGF; VEGFR; anti-angiogenesis; anti-angiogenic agents; tumor progression; immunosuppression; immunotherapy; immune-checkpoint inhibitors; combination therapy; tumor angiogenesis; endothelium; microenvironment; multiple myeloma; immunotherapy; anti-angiogenesis; adhesion molecules; immune-checkpoint inhibitor; tumor-derived exosomes; small extracellular vesicles; angiogenesis; cancer; tumor microenvironment; feline mammary carcinoma; VEGF-A; VEGFR-1; VEGFR-2; non-invasive biomarkers; angiogenesis; selectins; E-selectin; uproleselan; cancer; angiogenesis; adrenal fetal cortex; adrenocortical tumors; adrenocortical carcinoma; anti-angiogenic drugs; bFGF; VEGF; angiogenesis; anti-angiogenic therapy; resistance; cancer; vascular permeability; drug delivery system; microbeam radiation therapy (MRT); Chicken Chorioallantoic Membrane (CAM); U-87 Glioblastoma; ginsenoside Rg3; response surface methodology; optimisation; epimer; angiogenesis; multiple myeloma; long pentraxin 3; FGF/FGFR system; angiogenesis